Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial

Orest Szczurko, Neil Shear, Anna Taddio, Heather Boon, Orest Szczurko, Neil Shear, Anna Taddio, Heather Boon

Abstract

Background: Vitiligo is a common hypopigmentation disorder with significant psychological impact if occurring before adulthood. A pilot clinical trial to determine the feasibility of an RCT was conducted and is reported here.

Methods: 12 participants 12 to 35 years old were recruited to a prospective open-label pilot trial and treated with 60 mg of standardized G. biloba two times per day for 12 weeks. The criteria for feasibility included successful recruitment, 75% or greater retention, effectiveness and lack of serious adverse reactions. Effectiveness was assessed using the Vitiligo Area Scoring Index (VASI) and the Vitiligo European Task Force (VETF), which are validated outcome measures evaluating the area and intensity of depigmentation of vitiligo lesions. Other outcomes included photographs and adverse reactions. Safety was assessed by serum coagulation factors (platelets, PTT, INR) at baseline and week 12.

Results: After 2 months of recruitment, the eligible upper age limit was raised from 18 to 35 years of age in order to facilitate recruitment of the required sample size. Eleven participants completed the trial with 85% or greater adherence to the protocol. The total VASI score improved by 0.5 (P = 0.021) from 5.0 to 4.5, range of scale 0 (no depigmentation) to 100 (completely depigmented). The progression of vitiligo stopped in all participants; the total VASI indicated an average repigmentation of vitiligo lesions of 15%. VETF total vitiligo lesion area decreased 0.4% (P = 0.102) from 5.9 to 5.6 from baseline to week 12. VETF staging score improved by 0.7 (P = 0.101) from 6.6 to 5.8, and the VETF spreading score improved by 3.9 (P < 0.001)) from 2.7 to -1.2. There were no statistically significant changes in platelet count, PTT, or INR.

Conclusions: The criteria for feasibility were met after increasing the maximum age limit of the successful recruitment criterion; participant retention, safety and effectiveness criteria were also met. Ingestion of 60 mg of Ginkgo biloba BID was associated with a significant improvement in total VASI vitiligo measures and VETF spread, and a trend towards improvement on VETF measures of vitiligo lesion area and staging. Larger, randomized double-blind clinical studies are warranted and appear feasible.

Trial registration: Clinical trials.gov registration number NCT00907062.

Figures

Figure 1
Figure 1
Baseline and week 12 VASI scores. Graph of individual participants' Vitiligo Area Scoring Index scores at baseline and end of study (week 12).

References

    1. Whitton ME, Ashcroft DM, Barrett CW, Gonzalez U. Interventions for vitiligo [Systematic Review] Cochrane Database of Systematic Reviews. 2007.
    1. Sehgal VN, Srivastava G. Vitiligo: compendium of clinico-epidemilogical features. Indian Journal of Dermatology, Venerology and Leprology. 2007;73(3):149–156. doi: 10.4103/0378-6323.32708.
    1. Parsad D, Pandhi R, Juneja A. Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clinical & Experimental Dermatology. 2003;28(3):285–287.
    1. Halder RMMDa, Nootheti PKMDb. Ethnic skin disorders overview. [Miscellaneous] Journal of the American Academy of Dermatology. 2003;48((6 Part 2) Supplement):S143–S148. doi: 10.1067/mjd.2003.274.
    1. Behl PN, Bhatia RK. 400 cases of vitiligo - A clinicotherapeutic analysis. Indian Journal of Dermatology. 1971;17:51–53.
    1. Mehta HR, Shah KC, Theodore C. Epidemiological study of vitiligo in Surat area, South Gujarat. Indian Journal of Medical Research. 1973;61:145–154.
    1. Barona M, Arrunategui A, Falabella R, Alzate A. An epidemiologic case-control study in a population with vitiligo. Journal of the American Academy of Dermatology. 1995;33(4):621–625. doi: 10.1016/0190-9622(95)91282-7.
    1. Ongenae K, Beelaert L, Van Geel N, Naeyaert JM. Psychosocial effects of vitiligo. Journal of the European Academy of Dermatology & Venereology. 2005;20:1–8.
    1. Porter J, Beuf AH, Nordlund JJ, Lerner AB. The effect of vitiligo on sexual relationships. Journal of the American Academy of Dermatology. 1990;22(1 Pt. 1):221–222. doi: 10.1016/0190-9622(90)70028-G.
    1. Porter J, Beuf AH, Nordlund JJ, AB L. Response to cosmetic disfigurement: Patients with vitiligo. Cutis. 1987;39(6):493–494.
    1. Grimes PEMD. New Insights and New Therapies in Vitiligo. [Miscellaneous Article] JAMA. 2005;293(6):730–735. doi: 10.1001/jama.293.6.730.
    1. Forschner T, Buchholtz S, Stockfleth E. Current state of vitiligo therapy--evidence-based analysis of the literature. [Review] [30 refs] Journal der Deutschen Dermatologischen Gesellschaft. 2007;5(6):467–475. doi: 10.1111/j.1610-0387.2007.06280.x.
    1. Chu CY, Liu YL, Chiu HC, Jee SH. Dopamine-induced apoptosis in human melanocytes involves generation of reactive oxygen species. British Journal of Dermatology. 2006;154(6):1071–1079. doi: 10.1111/j.1365-2133.2006.07293.x.
    1. Park ES, Kim SY, Na JI, Ryu HS, Youn SW, Kim DS, Yun HY, Park KC. Glutathione prevented dopamine-induced apoptosis of melanocytes and its signaling. Journal of Dermatological Science. 2007;47(2):141–149. doi: 10.1016/j.jdermsci.2007.03.009.
    1. Namazi M, Chee Leok G. Vitiligo and diet: a theoretical molecular approach with practical implications. Indian Journal of Dermatology, Venerology and Leprology. 2009;75(2):116–118. doi: 10.4103/0378-6323.48654.
    1. Szczurko O, Boon H. A systematic review of natural health product treatment for vitiligo. BMC Dermatology. 2008;8(2)
    1. Panin Ga, Strumia Rb, Ursini Fc. Topical [alpha]-Tocopherol Acetate in the Bulk Phase: Eight Years of Experience in Skin Treatment. [Article] Annals of the New York Academy of Sciences. 2004;1031:443–447. doi: 10.1196/annals.1331.069.
    1. Ichiro K, Aki MA, Kumiko E, Sang JB. Vitamin D3 and solar irradiation in the treatment of vitiligo vulgaris. [Miscellaneous] Journal of the European Academy of Dermatology & Venereology Supplement. 2002;16(Supplement 1):341.
    1. Shigetoshi S. Treatment of vitiligo with Vitamin D3 (tacalcitol). [Miscellaneous] Journal of the European Academy of Dermatology & Venereology Supplement. 2002;16(Supplement 1):275.
    1. Siddiqui AH, Stolk LML, Bhaggoe R, Hu R, Schutgens RBH, Westerhof W. L-Phenylalanine and UVA irradiation in the treatment of vitiligo. Dermatology. 1994;188(3):215–218. doi: 10.1159/000247142.
    1. Cormane RH, Siddiqui AH, Westerhof W, Schutgens RB. Phenylalanine and UVA light for the treatment of vitiligo. Archives of Dermatological Research. 1985;277(2):126–130. doi: 10.1007/BF00414110.
    1. Rong Y, Geng Z, Lau B. Ginkgo biloba attenuates oxidative stress in macrophages and endothelial cells. Free Radic Biol Med. 1996. pp. 121–127.
    1. Scholtyssek H, Damerau W, Wessel R, Schimke J. Antioxidative activity of ginkgolides agains superoxide in a aprotic environment. Chem Biol Interact. 1997;106:183–190. doi: 10.1016/S0009-2797(97)00067-7.
    1. Kim S. Effect of bioflavones of Ginkgo biloba against UVB-induced cytotoxicity in-vitro. J Dermatol. 2001;28:193–199.
    1. Woelk H, Arnoldt K, Kieser M, Hoerr R. Ginkgo biloba special extract EGb 761 in generalized anxiety disorder and adjustmet disorder with anxious mood: A randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Research. 2007;41:472–480. doi: 10.1016/j.jpsychires.2006.05.004.
    1. Marcilhac A, Dakine N, Bourhim N, Guillaume V, Grino M, Drieu K. Effect of chronic administration of Ginko biloba extract or ginkgolide on the hypothalamic-pituitary-adrenal axis in the rat. Life Sciences. 1998;62:2329–2340. doi: 10.1016/S0024-3205(98)00214-8.
    1. Hoerr R. Behavioural and psychological symptoms of dementia (BPSD): effects of EGb761. Pharmacopsychiatry. 2003;36(Suppl 1):S56–61.
    1. Jezova D, Duncko R, Lassanova M, Kriska M, Moncek F. Reduction of rise in blood pressure and cortisol release during stress by Ginkgo biloba extract (EGb 761) in healthy volunteers. Journal of Physiology and Pharmacology. 2002;53:337–348.
    1. Anonymous. Ginko biloba: Monograph. Alternative Medicine Review. 1998;3(1):54–57.
    1. World Health Organization. Note for guidance on clinical safety data management: definitions and standards for expidited reporting. 1995. CPMP/ICH.377/395.
    1. Taieb A, Picardo M. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Research. 2007;20:27–35. doi: 10.1111/j.1600-0749.2006.00355.x.
    1. Hamzavi I, Jain H, McLean D, Shapiro J, Haishan Z, Lui H. Parametric Modeling of Narrowband UVB Phototherapy for Vitiligo Using a Novel Quantitative Tool. Archives of Dermatology. 2004;140:677–683. doi: 10.1001/archderm.140.6.677.
    1. Schulpis CH, Antoniou C, Michas T, Strarigos J. Phenylalanine plus Utraviolet Light: Preliminary Report of a Promising Treatment for Childhood Vitiligo. Pediatric Dermatology. pp. 332–335.
    1. Birlea S, Birlea M, Cimponeriu D, Apostol P, Cosgarea R, Gavrila L, Tigan S, Costin G, Das P. Autoimmune diseases and vitamin D receptor Apa-I polymorphism are associated with vitiligo in a small inbred Romanian community. Acta Dermato-Venereologica. 2006;86(3):209–214. doi: 10.2340/00015555-0093.
    1. Nicolaidu E, Antoniou C, Stratigos A, Katsambas AD. Narrowband ultraviolet B phototherapy and 308-nm excimer laser in the treatment of vitiligo: a review. Journal of the American Academy of Dermatology. 2009;60(3):470–477. doi: 10.1016/j.jaad.2008.07.053.
    1. Chan P, Xia Q, Fu P. Ginkgo biloba leaf extract: biological, medicinal, and toxicological effects. Journal of Environmental Science and Helath Part C. 2007;25:211–244. doi: 10.1080/10590500701569414.
    1. Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Annals of Internal Medicine. 2002;136:42–53.
    1. Natural Standard. Ginkgo (Ginkgo biloba) Monograph. 2008.
    1. Dugoua J-J, Mills E, Perri D, Koren G. Safety and efficacy of Ginkgo (Ginkgo biloba) during pregnancy and lactation. Canadian Journal of Clinical Pharmacology. 2006;13(3):e277–e284.
    1. Health Canada. Adverse Drug Reaction Database. 2008.
    1. Sparreboom A, Cox CM, Acharya RM, Figg DW. Herbal Remedies in the United States: Potential Adverse Interactions with Anticancer Agents. Journal of Clinical Oncology. 2004;22(12):2489–2503. doi: 10.1200/JCO.2004.08.182.
    1. Koek MB SV, van Weelden H, Steegmans PH, Bruijnzeel-Koomen CA, Buskens E. Cost effectiveness of home ultraviolet B phototherapy for psoriasis: economic evaluation of a randomised controlled trial (PLUTO study) BMJ. 2010;340(April 20):1490. doi: 10.1136/bmj.c1490.
    1. Koranne R, Sachdeva K. Vitiligo. International Journal of Dermatology. 1988;27(10):676–681. doi: 10.1111/j.1365-4362.1988.tb01260.x.
    1. Scherschun L, Kim J, Lim HW. Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo. J Am Acad Dermatol. 2001;44(6):999–1003. doi: 10.1067/mjd.2001.114752.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit